Formic Ventures

Formic organizes its investments around two poles: seed-stage biotechnology companies aimed at extending healthy human lifespan, and opportunistic startups that it believes make human life more meaningful. The firm frames this dual mandate as 'fighting entropy.' No single portfolio company has been publicly confirmed under either category, but the thesis gives it an unusually wide aperture for a specialized seed fund.

Formic is a seed-stage investor. It targets startups at their earliest institutional round, whether the founding team is building a longevity biotech platform or a consumer or enterprise product. The firm has not disclosed any later-stage or growth-equity activity.

The firm's website includes a 'Foundation' page, which indicates a parallel philanthropic effort, but no details about its structure, leadership, endowment, or grantmaking activity are publicly available. It is unclear whether the foundation shares governance or investment staff with the venture firm.

Publicly, Formic names two broad domains. The first is biotechnology with a specific focus on human longevity. The second is an opportunistic bucket that its own language suggests includes robotics, artificial intelligence, consumer platforms, and enterprise software — any technology that can, in the firm's view, make human lives more meaningful.

Formic has not publicly described its sourcing model. Given its seed-stage, thesis-driven posture in longevity biotech and adjacent tech, it likely relies on founder networks, academic lab spinouts in the Bay Area, and relationships with other early-stage investors, but any specific sourcing channel remains unconfirmed.